MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.060
-0.380
-8.56%
Closed 16:00 12/06 EST
OPEN
4.480
PREV CLOSE
4.440
HIGH
4.611
LOW
4.050
VOLUME
227.04K
TURNOVER
--
52 WEEK HIGH
6.59
52 WEEK LOW
2.000
MARKET CAP
114.25M
P/E (TTM)
-1.5861
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NLTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NLTX News

  • Neoleukin Therapeutics Announces Scientific Advisory Board
  • GlobeNewswire.2d ago
  • The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
  • Benzinga.11/27 12:26
  • Mid-Morning Market Update: Markets Edge Higher; Best Buy Profit Tops Expectations
  • Benzinga.11/26 15:18
  • The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
  • Benzinga.11/26 13:06

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About NLTX

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
More

Webull offers Neoleukin Therapeutics Inc (NLTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.